Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

beta-Thalassemia 1Supratentorial Brain Tumor Surgery 1Post-operative Residual Curarization 1Neoplasms 1Hepatoblastoma 1Brain Neoplasms 1

Interventions

Radiosurgery 12Temozolomide 10Radiotherapy 10Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 6Bevacizumab 6Surgical Procedures, Operative 5Pemetrexed 5Gefitinib 5Drug Therapy 5Carboplatin 5pyrotinib 4icotinib 4aumolertinib 4Trastuzumab 3Spermine Synthase 3Radiation 3Lomustine 3Etoposide 3Dexmedetomidine 3Chlorotoxin 3Carmustine 3osimertinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thiotepa 2Surveys and Questionnaires 2Sevoflurane 2Propofol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Brain Neoplasms × Sugammadex × Clear all
NCT05202899 2022-03-09

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Guangzhou General Hospital of Guangzhou Military Command

Phase 4 Unknown
40 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡